Original Source(s)
Related Content
Two ‘forever chemicals’ associated with higher risk of aggressive breast cancer in NIH analysis
November 5, 2026
ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT
Antonio Gioradano, MD, presents efficacy and safety of atirmociclib + fulvestrant in HR+/HER2- advanced breast cancer after progressing on prior CDK4/6 inhibitor - data from phase 2 FOURLIGHT-1 study.
November 17, 2026
-
1 min